Madrigal Pharmaceuticals, Inc.
MDGL
$301.66
-$6.12-1.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -465.89M | -518.67M | -510.45M | -444.28M | -373.63M |
| Total Depreciation and Amortization | 1.10M | 875.00K | 712.00K | 571.00K | 527.00K |
| Total Amortization of Deferred Charges | 2.09M | 2.36M | 2.55M | 2.64M | 2.41M |
| Total Other Non-Cash Items | 79.48M | 76.60M | 71.82M | 58.39M | 49.74M |
| Change in Net Operating Assets | -72.35M | 7.82M | -13.59M | -6.64M | -3.28M |
| Cash from Operations | -455.57M | -431.02M | -448.96M | -389.32M | -324.23M |
| Capital Expenditure | -1.46M | -2.30M | -1.86M | -1.80M | -1.48M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -272.92M | -586.26M | -334.11M | -215.80M | -501.04M |
| Cash from Investing | -274.39M | -588.56M | -335.97M | -217.60M | -502.52M |
| Total Debt Issued | -- | 0.00 | 15.00M | 30.00M | 65.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 735.06M | 1.20B | 1.19B | 1.09B | 530.48M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -75.00K | -150.00K | -363.00K |
| Cash from Financing | 735.06M | 1.20B | 1.21B | 1.12B | 595.12M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.10M | 175.63M | 422.40M | 509.21M | -231.63M |